RespireRx Pharmaceuticals

OverviewSuggest Edit

RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

TypePublic
Founded1988
HQGlen Rock, US
Websiterespirerx.com

Latest Updates

Employees (est.) (Dec 2018)2(-33%)
Revenue (FY, 2015)$86.9 K(+41%)
Share Price (May 2020)$0 (-1%)

Key People/Management at RespireRx Pharmaceuticals

Kathryn MacFarlane

Kathryn MacFarlane

Director

RespireRx Pharmaceuticals Office Locations

RespireRx Pharmaceuticals has an office in Glen Rock
Glen Rock, US (HQ)
126 Valley Rd
Show all (1)

RespireRx Pharmaceuticals Financials and Metrics

RespireRx Pharmaceuticals Revenue

RespireRx Pharmaceuticals's revenue was reported to be $86.92 k in FY, 2015
USD

Net income (Q1, 2020)

(946.7k)

EBIT (Q1, 2020)

(520.6k)

Market capitalization (21-May-2020)

430.0k

Closing stock price (21-May-2020)

0.0

Cash (31-Mar-2020)

81.0

EV

1.5m
RespireRx Pharmaceuticals's current market capitalization is $430 k.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.1m48.3k61.7k86.9k

General and administrative expense

3.2m1.9m933.0k3.8m3.6m5.3m2.5m1.5m1.1m

R&D expense

2.2m826.7k206.9k591.8k1.7m3.2m1.7m688.3k599.3k

Operating expense total

5.4m2.8m1.1m4.4m5.3m8.5m4.2m2.2m1.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

1.1m2.1k48.3k74.5k12.4k

Cost of goods sold

163.0k310.0k

General and administrative expense

803.7k730.0k731.4k756.0k389.4k759.3k104.2k29.6k2.3m207.3k792.9k229.9k800.4k1.6m1.5m1.4m1.3m989.9k918.3k356.3k354.8k432.9k330.6k324.5k270.4k279.9k365.3k

R&D expense

645.2k444.5k203.0k264.3k191.9k83.9k75.0k28.8k64.1k80.4k171.8k440.8k272.3k405.7k917.1k926.9k899.5k430.8k631.2k236.9k151.3k153.9k173.0k149.4k148.0k150.5k155.3k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.6m152.2k14.4k162.8k53.2k92.0k84.9k33.3k16.7k

Accounts Receivable

116.0m

Prepaid Expenses

85.6k17.0k2.4k29.1k42.9k38.9k28.6k

Inventories

4.6m
USDY, 2020

EV/EBIT

-2.9 x

EV/CFO

-85.9 x
Show all financial metrics

RespireRx Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase II Trials Products

4

Preclinical Phase Products

1
Show all operating metrics

RespireRx Pharmaceuticals Online and Social Media Presence

Embed Graph

RespireRx Pharmaceuticals News and Updates

RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report

Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”) indications, with a focus on obstructive sleep apnea, attention deficit hyperactivity disorder (“AD…

RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia

Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into a non-bi…

RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors

Glen Rock, N.J, Jan. 03, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of medicines that promote neuronal signaling in diseases and disorders of neuronal dysfunction, is plea…

RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.

Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on September 4, 2018, it entered into a dronabinol Development and Supply Agreement (“Agreement”) with N…

RespireRx Pharmaceuticals Blogs

RespireRx Pharmaceuticals Frequently Asked Questions

  • When was RespireRx Pharmaceuticals founded?

    RespireRx Pharmaceuticals was founded in 1988.

  • Who are RespireRx Pharmaceuticals key executives?

    RespireRx Pharmaceuticals's key executives are Kathryn MacFarlane.

  • How many employees does RespireRx Pharmaceuticals have?

    RespireRx Pharmaceuticals has 2 employees.

  • Who are RespireRx Pharmaceuticals competitors?

    Competitors of RespireRx Pharmaceuticals include Medizone International, Futura Medical and IntelGenx.

  • Where is RespireRx Pharmaceuticals headquarters?

    RespireRx Pharmaceuticals headquarters is located at 126 Valley Rd, Glen Rock.

  • Where are RespireRx Pharmaceuticals offices?

    RespireRx Pharmaceuticals has an office in Glen Rock.

  • How many offices does RespireRx Pharmaceuticals have?

    RespireRx Pharmaceuticals has 1 office.